Aspire-Lakewood Holdings, Inc.
ASBP
Positions held
Your positionsASBP isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $11.64M | Enterprise value | -$525,910 | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 0.91 | Beta | 0.17 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | -25.0% | Operating margin | -38.8% |
| Profit margin | 0.0% | ROE | -10.3% | ROA | 60.6% | Debt / equity | — |
| Current ratio | 7.99 | Free cash flow | $7.43M | Analyst recommendation | none | Mean target | — |
| 52w high | $18.76 | 52w low | $0.11 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -3880.6% | -5806.0% | -43403.5% | -59015.8% | — | — |
| Net income | -$1.3M | -$3.2M | -$4.7M | -$1.9M | -$2.0M | — |
| Gross margin | -47.7% | 20.3% | -23.5% | 45.5% | — | — |
| Gross profit | -$0.0M | $0.0M | -$0.0M | $0.0M | $0.0M | — |
| Operating income | -$2.4M | -$1.6M | -$1.8M | -$1.1M | -$0.8M | — |
- Revenue +123% vs prior quarter ($0.1M vs $0.0M).
- Gross margin -47.7% (was 20.3% prior quarter).
- Operating margin expanded to -3880.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | -312016.9% | — | — | — |
| Net income | -$24.5M | -$1.3M | $4.5M | -$0.6M |
| Gross margin | -1.9% | — | — | — |
| Gross profit | -$0.0M | $0.0M | $0.0M | $0.0M |
| Operating income | -$19.4M | -$1.2M | -$1.3M | -$0.6M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-09 · Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program
2026-09-08 · Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.
2026-08-18 · Sidoti Events, LLC's August Micro-Cap Virtual Conference
2026-08-13 · Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th
2026-08-11 · EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS Deal
2026-08-10 · EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS Deal
2026-07-20 · Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)
Price (daily)
Full chart · RSI · MACD · patterns